First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
Conclusion. Considering the findings of this study, osimertinib appears to be an effective and safe treatment option for patients with poor PS and advanced NSCLC harboring sensitiveEGFR mutations. To obtain conclusive results, further studies with larger cohorts are warranted.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Interstitial Lung Disease | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Study | Women